CARMAT |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.8 EUR | +0.53% |
|
+0.53% | -43.28% |
| Mar. 25 | Carmat: final agreement with creditors | CF |
| Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
| Sales 2023 * | 8.1M 8.64M | Sales 2024 * | 25.94M 27.66M | Capitalization | 93.67M 99.91M |
|---|---|---|---|---|---|
| Net income 2023 * | -49M -52.26M | Net income 2024 * | -35M -37.33M | EV / Sales 2023 * | 17.7 x |
| Net Debt 2023 * | 49.63M 52.94M | Net Debt 2024 * | 78.97M 84.22M | EV / Sales 2024 * | 6.66 x |
| P/E ratio 2023 * |
-1.83
x | P/E ratio 2024 * |
-2.99
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | +0.53% | ||
| 1 week | +0.53% | ||
| Current month | -7.65% | ||
| 1 month | -3.80% | ||
| 3 months | -15.84% | ||
| 6 months | +18.75% | ||
| Current year | -43.28% |
1 week
3.72
3.89
1 month
3.724.40
Current year
3.667.72
1 year
3.009.99
3 years
3.0031.70
5 years
3.0036.00
10 years
3.0096.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 3.8 | +0.53% | 19 922 |
| 24-04-22 | 3.78 | -0.66% | 20,171 |
| 24-04-19 | 3.805 | +0.13% | 16,870 |
| 24-04-18 | 3.8 | 0.00% | 16,491 |
| 24-04-17 | 3.8 | +0.53% | 13,548 |
Real-time Euronext Paris, April 23, 2024 at 08:23 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.78
EUR
Average target price
14.22
EUR
Spread / Average Target
+276.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.28% | 99.71M | |
| +9.42% | 125B | |
| -8.52% | 10.48B | |
| -3.67% | 8.42B | |
| +10.71% | 6.82B | |
| +24.48% | 4.96B | |
| +7.41% | 3.41B | |
| -0.91% | 3.04B | |
| -10.69% | 2.1B | |
| -11.48% | 1.97B |
- Stock Market
- Equities
- ALCAR Stock
